---
title: "Amotiv Rectifies Late Director Interest Notice After Performance Rights Lapse"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/280084123.md"
description: "Amotiv Rectifies Late Director Interest Notice After Performance Rights Lapse"
datetime: "2026-03-23T02:02:15.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280084123.md)
  - [en](https://longbridge.com/en/news/280084123.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280084123.md)
---

# Amotiv Rectifies Late Director Interest Notice After Performance Rights Lapse

Amotiv Rectifies Late Director Interest Notice After Performance Rights Lapse

### Related Stocks

- [NOTV.US](https://longbridge.com/en/quote/NOTV.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [AM Investment Strategies LLC Sells 1,038 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/286522809.md)
- [US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug](https://longbridge.com/en/news/286394551.md)
- [Assessing Antero Midstream (AM) Valuation After Strong Multi‑Year Shareholder Returns](https://longbridge.com/en/news/286753485.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)